Zhejiang Toyouvax Biopharming

Zhejiang Toyouvax Biopharming, formerly known as Zhejiang Tianyuan Bio-Pharmaceutical, is a leading Chinese biotechnology company focused on the development and production of human vaccines. Headquartered in Hangzhou, the company utilizes advanced platforms for bacterial, viral, and recombinant vaccines, complemented by proprietary adjuvant technologies such as CpG HP021 and MF59. Its commercial portfolio includes quadrivalent influenza and meningococcal vaccines, while its active pipeline features a live attenuated varicella vaccine and candidates for COVID-19 and H7N9 influenza. After a history of ownership by global pharmaceutical giants Novartis and GSK, the company was acquired by Nanjing Huapai Bio-Pharmaceutical and now operates as a key subsidiary of Shandong Buchang Pharmaceuticals. Zhejiang Toyouvax is committed to meeting international quality standards and expanding its impact on global public health through innovative immunization solutions.